Steve Chaplin
Abstract
Open-access reader
Tofacitinib (Xeljanz) is an oral janus kinase (JAK) inhibitor indicated for the second‐line treatment of moderate to severe active rheumatoid arthritis in adults. This article discusses its properties, efficacy and adverse effects.
OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Tofacitinib (Xeljanz) is an oral janus kinase (JAK) inhibitor indicated for the second‐line treatment of moderate to severe active rheumatoid arthritis in adults. This article discusses its properties, efficacy and adverse effects.
Key concepts: Tofacitinib, Janus kinase inhibitor, Medicine, Janus kinase, Rheumatoid arthritis, Adverse effect, Internal medicine, Pharmacology